How to Get Leqvio (Inclisiran) in Delaware

What Leqvio Is, and the Question This Page Actually Answers

Leqvio (inclisiran) works as a small interfering RNA (siRNA) that suppresses PCSK9 messenger RNA in hepatocytes, thereby decreasing the amount of PCSK9 protein synthesized in the liver and ultimately lowering LDL cholesterol. Unlike the monoclonal antibody PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent), which sequester PCSK9 protein already present in circulation, inclisiran prevents PCSK9 from being made in the first place. The FDA approval of inclisiran permits its use alongside dietary modification and statin therapy at the highest tolerated dose in patients with familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional LDL cholesterol reduction. The prescribing information for inclisiran can be obtained from the FDA, though a persistent URL reference was not confirmed at the time of writing.

The useful question for a Delaware reader is not whether inclisiran lowers LDL-C. It is which parts of the access process are fixed by federal approval and clinical evidence, and which parts depend on a specific insurer's current prior authorization policy, a specific pharmacy's network status, or a price that can change without notice. Conflating the two categories is the most common source of wasted time in this process, and it is the organizing idea behind the checklist below.

The Evidence Behind Inclisiran, Stated Carefully

The pivotal trials supporting inclisiran's approval were two parallel phase 3 studies enrolling adults with ASCVD or ASCVD-risk-equivalent conditions including HeFH, all on maximally tolerated statin therapy. Across roughly 17 months of follow-up, inclisiran produced a substantial, sustained reduction in LDL-C compared with placebo, and injection-site reactions were more common with inclisiran than placebo, without a clear excess of liver enzyme abnormalities or myopathy. This is the trial evidence underlying the FDA approval described above.

The exact enrollment numbers, percentage reductions, and p-values that circulate in secondary summaries of these trials should be verified against the original New England Journal of Medicine publications before being repeated in patient materials or PA letters. This draft does not carry a specific PubMed identifier forward because the identifiers inherited from the prior version of this page could not be confirmed as pointing to the correct papers, and an incorrect citation is worse than a general description. A clinician preparing documentation should pull the primary trial reports directly from a journal or PubMed search rather than relying on a copied link.

Separately, an inclisiran cardiovascular outcomes trial (referred to in public trial registries as ORION-4) has been conducted. Whether its results have been published, and what they show, should be confirmed against ClinicalTrials.gov or the primary publication before being cited to a patient, since outcomes-trial timing and findings are the kind of claim that goes stale quickly.

Who Qualifies: FDA Label Criteria Versus Payer Add-Ons

The FDA label describes two indications: heterozygous familial hypercholesterolemia and established clinical ASCVD, both requiring background maximally tolerated statin therapy (with adjunct diet). That label language is stable and does not vary by state.

What does vary, often by payer and by year, is the specific LDL-C threshold, the requirement (or not) for a documented ezetimibe trial, and whether a genetic test or a clinical scoring system is required to document HeFH. A prior version of this article listed specific numeric thresholds for named Delaware insurers. Those thresholds are the kind of fact that changes with formulary updates and could not be verified as current at the time of this draft, so they have been removed rather than repeated as if fixed. Anyone submitting a prior authorization request should pull the payer's current inclisiran policy document rather than relying on a remembered or previously reported threshold.

Patients who do not meet either FDA-approved indication sometimes ask about compounded inclisiran-type preparations from a 503A pharmacy. Compounded preparations are not FDA-approved, have not gone through the same trial evidence as Leqvio, and may differ in composition or bioavailability. The FDA maintains general guidance on outsourcing facilities and compounding oversight. (FDA, human drug compounding) A decision to use a compounded product instead of the FDA-approved drug is a site-level, individualized clinical judgment that should involve informed consent about the difference in regulatory status and evidence base, not a default workaround for cost or eligibility barriers.

Getting Evaluated: In-Person and Telehealth Options in Delaware

Because inclisiran is administered by a clinician rather than self-injected, a telehealth visit can reasonably serve as the initial evaluation in many cases, provided the prescriber holds an active Delaware license and the encounter meets the standard of care for starting a new lipid-lowering therapy: reviewing the lipid panel, confirming the indication, and screening for contraindications. Delaware's specific telehealth statute language and any recent amendments should be checked directly rather than assumed, since telehealth rules are amended periodically.

Nurse practitioners and physician assistants can prescribe inclisiran within their scope of practice, which in Delaware depends on their collaborative or supervising-physician agreement covering lipid management. The exact scope-of-practice rules for NPs and PAs in Delaware, including any recent legislative changes, should be confirmed against the Delaware Board of Nursing or Board of Medical Licensure rather than assumed to be unchanged from a prior year.

A Verification Checklist: What's Fixed Versus What Changes

Use this checklist to separate facts that are stable because they come from FDA approval or trial evidence, from facts that depend on a specific insurer, pharmacy, or date and must be reconfirmed before you rely on them.

Stable, federal or clinical facts (do not require re-verification each visit):

• Inclisiran (Leqvio) is FDA-approved for HeFH and clinical ASCVD as an adjunct to statin therapy, confirm against the FDA label if precision matters for a specific patient.
• The dosing schedule is Day 1, Month 3, then every 6 months, per the FDA label.
• Inclisiran is administered by a health care professional; it is not a home self-injection product.
• Compounded inclisiran-type preparations are not FDA-approved and have not completed the same trial evidence base as Leqvio.

Date-sensitive facts you must verify before acting on them:

• The specific insurer's LDL-C threshold, statin-and-ezetimezetimibe trial requirements, and prior authorization turnaround time, pull the current policy document from the payer, not a remembered figure.
• Whether a specific specialty pharmacy is in-network for the patient's plan, and current shipping timelines.
• Delaware's telehealth prescribing statute language and any recent amendments.
• Delaware nurse practitioner or physician assistant scope-of-practice rules for prescribing non-statin lipid therapy.
• Leqvio's list price, copay assistance program terms, and any state pharmaceutical assistance program eligibility rules, these change and should be confirmed with the manufacturer and the specific program directly.
• Whether the inclisiran cardiovascular outcomes trial (ORION-4) has published results, and what those results show.

Before submitting a prior authorization, confirm:

• A fasting or appropriately calculated LDL-C value on current statin therapy, with a date the payer will accept.
• Documented statin trial (or documented intolerance) and, if the payer requires it, ezetimibe trial history.
• The correct ICD-10 code for the indication being claimed (HeFH versus ASCVD).
• The prescriber's current Delaware license number and NPI.

Lab Workup Before Starting

A baseline lipid panel on current statin therapy is the universally required data point. Because inclisiran is cleared through a hepatic pathway (the asialoglycoprotein receptor) and the pivotal trials excluded patients with significant renal impairment, many prescribers also obtain baseline liver enzymes and a creatinine or eGFR, and check glycemic status in patients with diabetes. The FDA label does not require dose adjustment for mild-to-moderate hepatic or renal impairment, but severe hepatic impairment was not studied. Exactly which labs a given Delaware payer requires, and how old they can be, is plan-specific and should be confirmed at the time of the PA request rather than assumed.

Prior Authorization: What to Expect, and What to Confirm

Delaware has consumer protection rules governing insurer response times for prior authorization requests generally, but the specific statutory citation and timeframes should be verified directly from the Delaware Department of Insurance rather than repeated from memory, since insurance regulations are amended. What is consistent across payers is the type of documentation typically requested: a dated lipid panel, statin (and sometimes ezetimibe) trial history, the diagnosis code supporting HeFH or ASCVD, and the prescriber's licensing information. If a request is denied, Delaware residents generally have a right to an external appeal through the state's insurance regulatory process; the current appeal window and process should be confirmed with the Delaware Department of Insurance before a denial deadline is assumed.

Delaware's Medicaid managed care program (Diamond State Health Plan) is reported to cover inclisiran with prior authorization for FH and ASCVD indications, with periodic redetermination. Because Medicaid preferred drug lists and redetermination intervals are updated on their own schedule, confirm current coverage terms with the Delaware Medicaid program or the specific managed care organization rather than relying on a prior year's summary.

Pharmacy Logistics

Leqvio is distributed through specialty pharmacy channels rather than a typical retail pharmacy pickup, and it requires cold-chain storage (refrigerated, per the FDA label). After a prior authorization is approved, the prescription is generally routed to a specialty pharmacy or the manufacturer's patient support program, which coordinates shipment to the administering clinical site. Which specific specialty pharmacies are in-network for a given plan, and how long shipping and scheduling take in practice, vary by plan and by the patient's chosen clinical site, and should be confirmed with the specialty pharmacy and prescriber's office at the time of the prescription rather than assumed from a general timeline.

Cost and Financial Assistance

Leqvio is a high-cost specialty biologic-class therapy. Novartis has historically operated a copay assistance program for eligible commercially insured patients and a patient assistance program for uninsured or underinsured patients, and Delaware administers its own prescription assistance program for qualifying low-income residents. Specific price points, copay caps, and income eligibility thresholds change over time and should be confirmed directly with the manufacturer's current program materials and the Delaware Health and Social Services program office before a patient is told what they will pay out of pocket.

Transferring a Leqvio Prescription Into Delaware

A patient moving to Delaware with an active Leqvio prescription from another state will generally need a new prescription from a Delaware-licensed prescriber, because prior authorization approvals are tied to the prescribing state and payer network and do not automatically transfer. Bringing records documenting the original indication, baseline lipid panel, statin history, and any prior PA approval letters will speed re-establishment of care. Because inclisiran is dosed every 6 months, a modest delay in re-establishing care around a move is unlikely by itself to cause an acute clinical event, but patients should not assume any specific delay is safe without discussing their individual situation with a prescriber, since this has not been formally studied as a "how long is too long" threshold.

Comparing Inclisiran to the Injectable PCSK9 Antibodies

Evolocumab and alirocumab are monoclonal antibodies against circulating PCSK9 protein, dosed every 2 weeks or monthly by the patient at home, with cardiovascular outcomes trial data (FOURIER for evolocumab, ODYSSEY OUTCOMES for alirocumab) supporting event reduction in high-risk patients. Inclisiran's LDL-C lowering is broadly comparable in trial populations, but its own dedicated cardiovascular outcomes data are, at the time of this draft, less established in the public record than the biologics' outcomes trials; the current status of inclisiran's outcomes trial should be verified before telling a patient that outcomes benefit is proven to the same degree. The practical difference most patients notice is dosing frequency: twice-yearly clinician-administered dosing for inclisiran versus frequent home self-injection for the antibodies. For patients with needle aversion or adherence challenges, that difference may be clinically meaningful even before outcomes data are fully compared, but it is a reasoning based on adherence physiology, not a claim that inclisiran has matched the antibodies' outcomes evidence.

What Is Established, What Is Plausible but Unproven, and What Is Not Established

Established: inclisiran is FDA-approved for HeFH and ASCVD as a statin adjunct, is dosed twice yearly after loading, is administered by a clinician, and produces substantial LDL-C reduction in the pivotal trial population.

Plausible but not confirmed in this draft: the specific magnitude of cardiovascular outcomes benefit from inclisiran itself, since the outcomes trial's published status was not verified here; the degree to which twice-yearly dosing translates into better real-world LDL-C control than frequent self-injected antibodies, which is a reasonable inference from adherence literature in general but not a head-to-head outcomes comparison.

Not established, or not something this page can respond with confidence about: any specific Delaware insurer's current LDL-C threshold or PA turnaround time, any specific cash price, any specific specialty pharmacy's current network status, or the current text of Delaware's telehealth and NP/PA scope-of-practice statutes. These require direct verification at the time a reader acts.